



VIA HAND DELIVERY OCTOBER 6TH, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wei et al.

Application Serial No.: 10/086,882

Art Unit: 1646

Filed: March 4, 2002

Examiner: Mertz, P.

For: Chemokine-Alpha 6

Attorney Docket No.: PF458D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AP listed on the attached Form PTO/SB/08. A copy of reference AP is provided.

Copies of references AA-AE and AJ-AO were submitted by Applicants, and references AF-AI were cited by the Examiner in connection with United States Patent Application Serial No. 09/177,304, filed October 23, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/177,304 for copies of references AA-AO.


Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any

of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425.

Respectfully submitted,




Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Dated: October 6, 2004

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850
(240) 314-1224 (phone)

Enclosures

MJH/BM/lcc



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/086,882-Conf. #2419
				Filing Date	March 4, 2002
				First Named Inventor	Ying-Fei Wei
				Art Unit	1646
				Examiner Name	P. M. Mertz
Sheet	1	of	1	Attorney Docket Number	PF458D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,236,829	08-17-1993	Farber et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁶
	AB	WO95/14772	06/01/1995	Matsubara	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AC	STRIETER, R.M. et al., The Journal of Biol. Chem., Vol. 270(45):27348-27357 (1995).		
	AD	ANGIOLILLO, A.L. et al., The Journal of Exp. Medicine, Vol. 182:155-162 (1995).		
	AE	PCT Search Report (PCT/US98/22513).		
	AF	HARLOW et al. (1988) Antibodies, A Laboratory Manual. Chapter 5, p.76. Cold Spring Harbor Laboratory.		
	AG	GEORGE et al. (1988) Macromolecular Sequencing and Synthesis. Chapter 12, pp.127-149. Alan R. Liss, Inc. New York.		
	AH	CUNNINGHAM et al. (1989) Science. Vol. 244:pp1081-1085.		
	AI	HILLIER et al. (May 1997) EMBL EST Database. Accession No. AA410918.		
	AJ	GenBank Accession No. AA410918 (05-18-97)		
	AK	GenBank Accession No. AA419299 (10-16-97)		
	AL	GenBank Accession No. AA411042 (05-18-97)		
	AM	GenBank Accession No. AA410950 (05-18-97)		
	AN	GenBank Accession No. AA325795 (04-20-97)		
	AO	GenBank Accession No. D20974 (07-30-96)		
	AP	GenBank Accession No. NP_061197 (09-03-04)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--